anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,921-130,980 of 319,975

filter-aware
122
The slide uses a Q&A transcript format to substantiate claims of industry-wide corruption and ongoing investigations.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
123
The slide uses a Q&A transcript format to substantiate claims of kickbacks in the organ transport industry.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
124
This slide serves as a transition or section header for a highly critical argument against the company.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
125
The slide uses a legal statute to frame the company's business model as criminal activity.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
126
The slide uses a narrative structure to explain a systemic loophole, supported by a direct excerpt from an official policy document.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
127
The slide uses a combination of narrative summary and direct excerpts from a Feb 2024 letter to expose flaws in the OPTN allocation system.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
128
The slide presents anecdotal evidence of systemic gaming of the organ allocation system.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
129
The slide uses a direct quote from a transplant surgeon to allege systemic gaming of the organ allocation system.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
130
Includes direct quotes from a transplant hepatologist at Mass General Hospital to support the thesis of perverse incentives.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
131
The slide uses a Q&A transcript format to highlight a competitor's critique of the subject company's business model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
132
The slide uses a 'villain' narrative framing, comparing the medical system to a cartel and highlighting the 'addiction to volume' as a driver for TransMedics service adoption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
133
The slide presents a narrative of systemic corruption and regulatory bypass involving TransMedics and OPOs.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
134
The slide uses a Q&A format to document expert testimony regarding potential kickbacks and regulatory circumvention.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
135
The slide uses a Q&A format to highlight alleged unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
136
The slide uses highlighted quotes from transplant surgeons to build a case for potential regulatory or ethical issues regarding TransMedics' business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
137
The slide uses a Q&A format to highlight a specific allegation of unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
138
The slide presents a Q&A format with a surgeon, highlighting allegations of unethical business practices and operational friction.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a Q&A format to present testimonial evidence of alleged misconduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
140
The slide uses a Q&A format to provide direct evidence of unethical behavior in the organ transplant system.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
141
The slide uses a Q&A format to highlight alleged procedural violations. The yellow highlighting emphasizes the specific claims of bypassing the OPO.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
142
Includes a Q&A transcript excerpt highlighting potential ethical/regulatory concerns regarding organ allocation and communication methods.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
143
The slide uses a 'smoking gun' narrative to frame the testimonial as evidence of unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
144
Includes a Q&A transcript excerpt as evidence for the allegations.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
145
The slide uses a Q&A format to present testimony from an industry veteran, highlighting allegations of unethical sales practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
146
The slide uses a Q&A format to highlight potential regulatory violations by TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
147
The slide uses a combination of summary text and a direct quote from a high-volume user to substantiate the claim of unethical organ allocation practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
148
The slide uses a Q&A format to highlight alleged unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
149
The slide uses screenshots of the UNOS/UNet portal to establish the system's official status and legal warnings.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
150
The slide uses a Q&A transcript format to highlight potential ethical concerns regarding vendor access to sensitive medical data.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
151
The slide presents two Q&A excerpts from a transplant surgeon to support the claim that TransMedics is hijacking the organ allocation process.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
152
The slide uses direct quotes from industry experts to build a case against TransMedics' business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
153
The slide uses a Q&A format to highlight potential misuse of system access.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
154
Includes a direct quote from an unnamed source regarding the company's technicians.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a 'fraud-exposure' framework to contrast alleged real-world usage with official FDA labeling.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses a combination of qualitative expert interview summaries and quantitative data from the company's own investor presentation to frame the company's clinical claims as a 'ruse'.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
157
The slide uses a testimonial to undermine the corporate narrative of 'Game Changer' technology, suggesting it is instead a tool for labor convenience.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
158
The slide uses a testimonial/interview format to challenge the necessity of the OCS device for local transplants.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
159
The slide uses Q&A transcripts to undermine a business model premise.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
160
The slide uses direct quotes from transplant directors to challenge the value proposition of TransMedics' NOP service.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a Q&A format to substantiate the claim of reckless off-label usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
162
The slide uses a Q&A format to present expert testimony regarding potential misuse of medical devices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
163
The slide uses direct quotes to expose a misalignment between the stated value proposition (reduced hospitalization) and the actual usage (scheduling convenience).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a primary headline followed by a detailed supporting quote, highlighting the ethical and financial concerns regarding off-label use of perfusion technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
165
The slide uses a Q&A format to present a negative testimonial/critique of the company's sales tactics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
166
The slide uses direct quotes from UCSF hospital administrators to frame the argument that TransMedics usage is being curtailed due to cost and lack of clinical indication.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
167
Uses direct quotes from surgeons at Utah and UCSD to support the thesis of off-label, convenience-driven usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
168
The slide uses direct quotes to highlight a discrepancy between the purported clinical value of the device and the actual operational use case.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses direct quotes from anonymous experts to build a case of 'expensive abuse' of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a Q&A transcript format to build a case against the clinical justification of the product's usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
171
The slide uses expert quotes to frame 'back to base' usage as a potentially harmful, off-label practice driven by convenience rather than clinical necessity.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a Q&A format to highlight a specific industry pain point regarding the misuse of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
173
The slide highlights a specific operational failure (delayed pump usage) causing a 10% loss rate in the region.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
174
The slide contrasts the author's claims of widespread off-label use with the official FDA 'Indications for Use' text.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a 'villain_critique' approach by quoting an ex-employee to expose what the author considers to be fraudulent medical claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
176
The slide uses a table from a JAMA Surgery paper to highlight the mean donor age in the trial (45.9 years) as evidence of selection bias.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
177
Includes a Q&A transcript excerpt highlighting the risks of off-label use beyond the 30-minute window.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
178
The slide uses expert quotes to argue that off-label use of perfusion pumps is limited by reputational risk and biological constraints.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
179
The slide uses a Q&A transcript format to highlight the discrepancy between regulatory guidelines and real-world surgical behavior.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
180
The slide uses a specific study to challenge the safety/efficacy claims of machine perfusion vendors like TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
181
The slide uses a combination of narrative summary and verbatim Q&A transcripts to highlight discrepancies between trial conditions and real-world usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit